Highlights

  • Racura is developing RC220, its proprietary formulation of the anticancer compound bisantrene.
  • The CPACS Phase 1 programme progressed to a higher RC220 dose cohort in May 2026.
  • The HARNESS-1 Phase 1 trial reported its first patient treated in June 2026.
  • The company announced fundraising initiatives totalling A$34.3 million in June 2026.
  • Clinical data, patient recruitment and financing remain central to its development programme.

Racura Oncology Limited (ASX:RAC) is an Australian clinical-stage biopharmaceutical company developing treatments for cancer. Its main investigational asset is RC220, a proprietary formulation of (E,E)-bisantrene. During 2026, the company advanced clinical studies in solid tumours and lung cancer while preparing a later-stage programme in acute myeloid leukaemia (AML). These programmes are at different stages of development and remain subject to clinical and regulatory assessment.

How RC220 Fits the Oncology Programme

RC220 is being investigated across several oncology settings rather than as an approved treatment for those indications. Racura Oncology Limited (ASX:RAC) describes bisantrene as a small-molecule anticancer agent whose activity includes interactions with G4-DNA and RNA and inhibition of the cancer-related regulator MYC. These mechanistic findings provide a scientific basis for development but do not establish clinical effectiveness in each targeted cancer.

The company’s programme includes CPACS, which studies RC220 alongside doxorubicin in advanced solid tumours, and HARNESS-1, which assesses RC220 combined with osimertinib in patients with EGFR-mutated non-small cell lung cancer. Racura Oncology Limited (ASX:RAC) is also progressing a Phase 3 programme for relapsed or refractory AML. Different trial designs mean that results in one population cannot automatically be extended to another.

CPACS and HARNESS-1 Milestones in 2026

On 15 May 2026, Racura reported that the safety review committee for CPACS had cleared an increase to the second dose cohort of 80mg/m². The decision followed review of the first three patients treated at 40mg/m², with no dose-limiting toxicities identified during the observation period. The announcement described an early safety assessment, not a demonstration of improved patient outcomes.

Racura Oncology Limited (ASX:RAC) subsequently reported on 25 June 2026 that the first patient in HARNESS-1 had received RC220 at 50 mg/m². Its release stated that no adverse events were observed during or after that infusion. Because this concerned an initial patient, broader conclusions about tolerability or treatment benefit require additional trial evidence.

FY26 Financial Position and Clinical Funding

Racura announced on 16 June 2026 that a series of fundraising initiatives had raised a total of A$34.3 million. The company stated that the proceeds would fund its announced clinical programmes in AML, lung cancer and the solid-tumour cardioprotection study, together with general working capital. Racura Oncology Limited (ASX:RAC) therefore linked the capital raising directly to clinical development expenditure rather than commercial product sales.

Its FY26 preliminary financial report recorded revenue from ordinary activities of A$613,291 and a loss attributable to shareholders of A$11,088,270 for the year ended 30 June 2026. These figures reflect a development-stage business, for which trial expenditure and available funding are significant components of financial reporting. Revenue should not be interpreted as evidence that RC220 is commercially established.

Clinical Execution and Development Considerations

Patient recruitment, trial dosing, safety reviews and eventual efficacy outcomes determine how the programmes advance. Racura Oncology Limited (ASX:RAC) also faces manufacturing, intellectual-property, regulatory and funding requirements before any investigational therapy could reach wider clinical use. Early pharmacokinetic or mechanistic observations should be distinguished from completed controlled evidence of clinical benefit.

Key Insights

Racura’s 2026 activity centres on advancing RC220 through defined clinical studies and supporting those studies with additional funding. The CPACS dose escalation and first HARNESS-1 treatment were documented operational steps; neither removes the uncertainty inherent in clinical development. Subsequent study results and formal company disclosures will provide the basis for assessing progress.